Grafa News and Videos — Page 332

Australia will spend $56.1 million over four years to phase out paper arrival cards and introduce digital passenger declarations at all international airports and seaports.

Anthropic said its planned $21.6 billion Australian infrastructure investment hinges on the federal government providing clear local copyright laws.

Paramount (NASDAQ:PSKY) faces a lawsuit from California and 11 other states seeking to block its proposed $110 billion acquisition of Warner Bros. Discovery (NASDAQ:WBD), with regulators alleging the deal could reduce competition in entertainment markets.

President Donald Trump said the United States was reinstating a naval blockade on Iran after Tehran claimed it had closed the Strait of Hormuz, a major global oil shipping route.

Intel (NASDAQ:INTC) announced a €5 billion ($5.7 billion) capital investment at its Leixlip campus in Ireland to expand production of data center processors supporting artificial intelligence and high-performance computing demand.

Halliburton (NYSE:HAL) secured major integrated well construction contracts for the GranMorgu deepwater development offshore Suriname, operated by TotalEnergies, covering drilling and completion services under a long-term program.

Artelo Biosciences (NASDAQ:ARTL) reported new nonclinical data showing ART27.13 reduced neuropathic pain-associated behaviors in a paclitaxel-induced peripheral neuropathy model in male and female animals.

BioMarin Pharmaceutical (NASDAQ:BMRN) announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application for full approval of VOXZOGO (vosoritide) in children with achondroplasia, with an FDA decision target date of February 28, 2027.

Virtus Investment Partners (NYSE:VRTS) reported preliminary assets under management of $152.2 billion and other fee-earning assets of $1.7 billion, bringing total client assets to $153.9 billion as of June 30, 2026.

Voyager Therapeutics (NASDAQ:VYGR) reported six-month toxicology results for VY1706, its investigational tau-targeted gene therapy for Alzheimer’s disease, showing s